Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 18, 2026

Modulation of WNT and FGF18 enhances yield and subtype identity of hPSC-derived midbrain dopamine neurons.

View Full Paper
Ask AI
Bookmark
Share

Authors

TKT KimMemorial Sloan Kettering Cancer CenterJPJinghua PiaoMemorial Sloan Kettering Cancer CenterVBVittoria Dickinson BocchiMemorial Sloan Kettering Cancer Center

Discussion

Loading...

Member takes

Implication

Randomized trial demonstrates improved yield of midbrain dopamine neurons in disease modeling, suggesting enhanced potential for Parkinson's therapy.

Key Points

  • This research aims to optimize the protocol for deriving midbrain dopamine neurons from human pluripotent stem cells to enhance yield and subtype identity.
  • Implemented an optimized differentiation strategy using FGF18 and IWP2 during the neurogenesis stage.
  • Conducted single-cell transcriptomic analysis and functional studies to assess neuron characteristics.
  • Utilized in vivo rat models to evaluate the functional impacts of the derived neurons.
  • Boost+ mDA neurons exhibited significantly higher TH+ expression rates, with improved yield and similarity to primary mDA neurons (p < 0.01).
  • In vitro tests revealed enhanced dopamine production and better electrophysiological properties compared to standard protocols.
  • In vivo studies showed efficient rescue of amphetamine-induced rotational behavior and improvement in ladder rung assays in 6-OHDA-treated rats.

Cite This Study

Kim et al. (2026) studied this question.

synapsesocial.com/papers/6a0aad2a5ba8ef6d83b70b35https://doi.org/10.1172/jci190954
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cryopreservable dopaminergic progenitors derived from human iPSCs with accelerated loss of pluripotency and early functional restoration in Parkinsonian rats2026
  2. 2Developmentally Guided Differentiation of Ventral Midbrain Dopaminergic Cells Validated in Proteopathy‐Based Parkinson's Disease Models2026
  3. 3Engineering functional ventral midbrain dopaminergic neurons in human organoids through WNT modulation and bioreactor culture2025
  4. 4Engineering functional ventral midbrain dopaminergic neurons in human organoids through WNT modulation and bioreactor culture2026
  5. 5Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors2025 · 7 citations